• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Treating and elevating children with ASD poses an unlimited burden. Despite the fact that infantile autism has been first described by Leo Kanner (1) as early as 1943, but the etiology of ASD shouldn't be completely understood. The genetic background of ASD contains heterogenic traits (2) which are described to be responsible for affecting the mind network sign conduction. However, causative treatment options are still not out there. The disease reveals a rise in incidence with climbing numbers up to 1 out of fifty four youngsters (3). While progress has been made in establishing a psychological and symptom tailored remedy, the search for biologic diagnostic parameters of the disease has grow to be a serious matter in current ASD analysis.

Several groups from Sweden, UK, and the USA offered valuable perception to understand the genetic background and threat elements for ASD (4-8). While some teams postulate that ASD are highly familial (7, 8), a last verdict on the underlying cause of ASD continues to be far away (2).

A milestone in ASD analysis was the finding that ASD may be induced by an interplay between genetic predisposition and immunological inflammatory elements (9-11). This changed paradigm of ASD conception opened the door to introduce biological (autologous or allogenic) stem cell therapies known amongst others for their immune-modulating properties (12, 13). In this context, an increasing variety of published investigations reporting on remedy attempts using either autologous or allogeneic bone marrow (BM) or umbilical derived pluripotent cells (14-19) have inspired us to report the results in a pilot group of children. Autologous BM-derived, level-of-care stem cell transplantation (SCT) was used on account of the truth that it carries virtually no risk with respect to antagonistic autoimmune response and for its common availability, because it doesn't exclude kids with out stored umbilical cord or entry to umbilical cord blood.

Two research making use of intrathecal instillation of autologous stem cells had been reported by Sharma et al. (14) from India and Thanh et al. (15) from Vietnam in small cohorts. To start out a new process in a geographical and political part of the world as large as the EU in our opinion warrants the report of small case studies, which undoubtedly ought to and can be followed by larger studies in due time. Thus our goal was to contribute to the restricted expertise acquired up to now by adding two elements to the described operative protocol: namely i.v. application of stem cells and the transfusion of bone marrow derived plasma, identified to be wealthy in cytokines, and growth components.

All children acquired state-of-the-artwork, non-invasive treatment as instructed by their specialists earlier than and after undergoing autologous, point-of-care SCT. For this retrospective case report, outcome was reported by the parents including the Autism Treatment Evaluation Checklist (ATEC) rating, which was accomplished online (https://www.autism.org/autism-treatment-analysis-checklist/). The ATEC, a questionnaire developed by the Autism Research Institute (San Diego, CA) (6), is broadly utilized in publications to describe adjustments over time. ATEC complete scores range from 0 to 179 factors and are determined by adding up the 4 sections (part I (0-28 points): speech/language/communication; section II (0-forty points): sociability; section III (0-36 points): sensory/cognitive consciousness; and part IV (0-75 factors): health/bodily/conduct). A better rating indicates a better level of impairment.

The target evaluation regarding progress and improvements in ASD encounters numerous difficulties. While there are already numerous diagnostic exams (e.g., Autism Diagnostic Observation Schedule, ADOS; Childhood Autism Rating Scale, Cars; Autism Diagnostic Interview - Revised, ADI-R), progress and enchancment are even tougher to assess. Diagnostic tests, corresponding to ADOS, typically require specialists for execution and the test per se was not developed to test for changes over time. Consequently, we decided to rely on the ATEC rating with all its limitations and benefits as has been finished in different publications on this field (16).

All SCTs were carried out as level-of-care procedures in a class IIa operating room with sterile air circulate. The following commonplace working procedure (SOP) was used: (1) anesthesia was ready with rectal administration of Midazolam (1mg/kg body weight with max. of 15mg); (2) slowly starting sedation with 5-8ml (i.v.) 1%-Propofol (sedoanalgesia); (3) positioning of the patient on one side following surgical washing and draping the anterior and posterior iliac crest; (4) injection of 2ml of 1%-Xylocaine at the planned puncture websites on the periosteum and subcutaneously; (5) aspiration of BM from the posterior and anterior iliac crest adopted by a switch of the BM aspirate to a sterile blood bag; (6) the BM aspirate was then processed in the operating room in line with the proprietary protocol using a fully automated cell separator (Sepax S-100; Biosafe S.A., Eysins, CH); (7) after lumbar puncture of the dural sac 2ml of cerebral spinal fluid (CSF) was routinely withdrawn in order to prevent excessive intrathecal strain secondary to injection of the stem cell concentrate; (8) intrathecal administration of the obtained BM concentrate (~1ml/10kg physique weight); and (9) i.v. administration of the remaining BM concentrate and plasma supernatant (10). Standard postoperative care was utilized.

Samples of BM aspirate/CSF and concentrate had been transferred to the identical laboratory instantly after SCT and have been analyzed with fluorescence activated cell sorter (FACS) utilizing a stem cell kit from Beckman Coulter and the ISHAGE protocol (https://www.bc-cytometry.com/PDF/DataSheet/IM3630.pdf). Stem cell counts including CD34+ and CD45+/leukocytes, which are known as oblique indicators for progenitor cells, had been obtained to quantify stem cells.

A summary of demographic, diagnostic, and laboratory knowledge and stem cell transplantation details of the 4 kids with ASD are introduced in Table 1.

Table 1. Demographic, diagnostic, and laboratory knowledge and stem cell transplantation particulars of the four kids with autism spectrum disorder (ASD).

Case Description

Case #1

The delivery, a planned caesarean part in the 38th week of pregnancy, of a boy from a 40-yr-outdated healthy mother and a 41-yr-old wholesome father, went without complications. The beginning physique weight and size had been 3340g and 51cm, respectively. The little one developed usually, like his older brother, until the age of 2 years. Thereafter, the dad and mom seen that the boy gradually lost the vocabulary he had already acquired with out comorbidity. At 2.5 years of age the child was non-verbal; thus, speech therapy was started. Since the speech therapy confirmed no success after about 1.5 years of implementation, the boy was evaluated in a particular clinic for psychiatry and diagnose with autism by Autism Diagnostic Observation Schedule (ADOS) ASD on the age of 4-years.

Immediately after the diagnosis, the little one started the so-known as ABA (Applied Behavior Analysis) therapy at residence (3h/day). Drug remedy with Atomoxetine (8mg oral/day), Risperidone (1mg/ml from 0.5 to 2 x 0.5ml/day), and Cerebrolysin® injection 2 x 2.5ml/week was not began till 6 months after diagnosis. Despite reasonable cognitive enhancements, there was no change in speech in response to the mother and the little one was weaned from all treatment. Finally, the dad and mom decided to let the child endure autologous SCT in our center.

The boy showed no minor or serious side effects. The dad and mom observed first impressions of a benefit of the SCT at the three months observe-up evaluation. After a year the little one improved primarily concerning speech (e.g., the baby began to formulate simple sentences with several phrases, to ask significant questions, and finally to have conversations), social behavior (e.g., he confirmed higher eye contact, obeyed higher, and had no extra tantrums), and in addition behavior regarding meals intake and hyperactivity. All accessible, mother and father-generated ATEC scores are presented in Figure 1A.

Figure 1. Autism remedy evaluation guidelines (ATEC) scores of (A) case #1, (B) case #2, (C) case #3, and (D) case #4 earlier than and after stem cell Children's stem cell transplantation (SCT).

Case #2

The only child of a healthy 25-yr-previous mom and a healthy 31-yr-outdated father was born within the 39th week of pregnancy by way of caesarean part as a consequence of umbilical cord malposition around the neck of the child. The delivery weight was 3600g and the body length 51cm. The first indicators of an ASD (e.g., did not respond to call, exhibits little eye contact) were already apparent in the first 12 months of life. On the age of three the boy was then diagnosed as autistic (F84.0) by a neuropsychiatrist. Dyspraxia (F82) was also found. Drug remedy with Cerebrolysin® injection 1-5ml/week, as well as behavior therapy (2h/day) was utilized as advisable by the specialist for a few years. At the age of 7.5, the language growth was retarded to the level of a three year old child. Based on recommendations BM-derived SCT of and exchanges with different dad and mom, the boy's dad and mom decided to have their son treated with autologous SCT.

The little one had no minor or severe unwanted side effects. Parents noticed important behavioral changes relating to hyperactivity, inflexible conduct, but additionally enhancements with unique digestive issues, sensitivity to noise, and anxiety 9 months after the autologous SCT. Significant behavioral changes relating to hyperactivity, inflexible behavior, but additionally improvements with original digestive issues, sensitivity to noise, and anxiety had been reported by the mother and father 9 months after the autologous SCT. All available, parents-generated ATEC scores are introduced in Figure 1B.

Case #3

The boy was born as a single little one to a 30-yr-outdated healthy mother and a 35-yr-previous healthy father via caesarean section attributable to umbilical cord malpositioning across the neck. The start body weight was 4,000g. The mom seen that her baby boy showed hardly any eye contact, did not react to names, and confirmed hardly any social interaction. However, a definitive prognosis of ASD was made by a psychiatrist later on on the age of three years. The youngster lagged proper speech improvement; in accordance with the dad and mom, he understands every part, however can not express himself. He was not treated with any medicine nor behavioral therapy as suggested by his physicians. The decision of the mother and father to go for autologous SCT was made on the boy's age of 14.5 years and was additionally primarily based on private communication with different dad and mom.

The boy confirmed no minor or critical side effects. Despite the advanced age, linguistic (e.g., he started to speak two-phrase sentences) and particularly sensory improvements equivalent to perceiving and reacting to the environment were seen by the mother and father. All accessible, mother and father-generated ATEC scores are presented in Figure 1C.

Case #four

The only woman on this case sequence was born because the little sister of a 2-year older boy to a 34-year-outdated wholesome mother and a 31-year-outdated healthy father through an elective caesarean section on the 38th week of pregnancy. The start weight was 3,180g and the body length 50cm. The girl developed normally, like his older brother, till the age of 1.5 years, thereafter the dad and mom noticed that her conduct was not the same as the older sibling (e.g., she was not reacting when known as, no eye contact, not speaking, and she all the time needed to be left alone). With 18 months the child was diagnosed as autistic by a neurologic pediatrician. Additionally, the lady was diagnosed with bronchial asthma requiring inhalation therapy. Immediately after analysis, the baby started ABA, which included 3h/day with a specialized psychotherapist and the remaining time ABA was continued with her mother. Because of only slight enhancements with 2-years of ABA therapy, the mother and father decided to let the youngster undergo autologous SCT. Deficits existed primarily relating to speaking, frustration, and concentration.

SCT was carried out without any minor or main complications. 3 months after the SCT, the woman confirmed improved initiative and studying behavior and was even in a position to remember the realized matter. Furthermore, she has no asthma anymore and the numbers of colds she used to have, significantly decreased. All out there, parents-generated ATEC scores are presented in Figure 1D.

Furthermore, mother and father reported that they had been very a lot glad (Case #1 and Case #3) or much glad (Case #2 and Case #4) with the procedure and that they might undergo SCT again. This satisfaction correlates with the ATEC score. Considering an ATEC complete rating between 31 and 50 factors as a average type of ASD and values beneath 30 points as a mild form, then ASD all cases changed from reasonable to mild type of ASD possibly in relation to autologous SCT (Figures 1A-D). No relapse has been noticed to date (1-2 years).

Discussion

With this report we present promising results regarding safety and efficacy suggesting application of autologous, BM-derived, intrathecally and concurrently intravenously utilized, point-of-care SCT in 4 children with ASD.

Immediate and Delayed Complications

Using sedation and local anesthesia, the procedure involving BM-biopsy and intrathecal instillation of remoted and concentrated BM stem cells resulted in no speedy or delayed minor or main opposed events. That is most probably attributed to stringent situation present within the operation theatre and experience of the surgeon and anesthetist. The submit-operative course during the following 48h was uneventful too as preventive non-steroidal anti-inflammatory drug pre-medication and anti-emetics had been prescribed.

Sharma et al. (14) in a bunch of 34 youngsters reported asides minor side effects together with nausea, vomiting, and local ache, a percentage of major adversarial events in 31% (10/32) comprising hyperactivity and epileptic seizures. Thanh et al. (15) reported no main adverse event in similarly sized examine on 30 children undergoing repeated interventions. In our pilot research we encountered neither speedy, nor delayed main hostile events.

Assessment of Treatment Outcome

In our small collection, treatment outcome reported over a follow-up period of 1-1.5 year relied on the suggestions of the dad and mom and ATEC score. We are conscious that mother and father reporting consequence is topic to bias and to a sure extent on behavioral non-compliance of the youngsters, in our context and just like a randomized managed trial using ATEC as primary endpoint (16), parental-reported ATEC proved to be reliable to evaluate longitudinal outcome.

Despite the presence of professional rating tools similar to ADOS, Cars, and ADI-R to diagnose and consider ASD, such tools might have drawback in daily apply. As well as, the dependency on numerous sources to acquire a extra full clinical picture has been advocated (17).

Diagnostic exams are mainly not properly suited to judge changes over time and as such do require specialists for execution. Especially in patients with ASD and every day fluctuations, parental assessment with their steady observation of behavioral and developmental changes, could also be a significant benefit to single time level assessments.

However, one confounder is that neither standardized test nor parental observations can account for the inherent nature of Ads signs and their improvements over time. In our collection, the enrolment of the youngsters to endure the SCT procedure was motivated by the frustration of dad and mom a earlier lack of enchancment.

Efficacy of the Procedure

Following SCT, reported ATEC scores revealed important enhancements in all ATEC subgroups together with speech/communication, social conduct, sensory/cognitive consciousness, health/physical/conduct in comparison with pretreatment standing. Such amelioration not solely improved the speedy quality of life of the kids and their surroundings, however can also contribute to the kids's future ability to conduct an impartial life in a protected environment. Hence, from an economical standpoint, such improvements could lead to vital reductions of continuously incurring care prices with age.

Comparable to our therapy approach making use of autologous BM-derived intrathecally applied SCT, two investigations -one making use of a single (14) and the other two- intrathecal (15) stem cell instillations additionally reported encouraging outcomes. Mixed outcomes were reported using intravenous supply of both, autologous or allogenic, umbilical cord blood-derived SCT. Two studies reported vital enhancements (18, 19), while the remaining two only a pattern towards enchancment in a sub-analysis in children with out mental incapacity (20, 21). Details hereto are summarized in Table 2. Intrathecal utility was favored by us on these clinical and also theoretical grounds. Stem cells are too massive to cross the blood mind barrier, hence, they have to be utilized directly into the CSF by way of intrathecal route so as to reach the mind.

Table 2. Published investigations reporting intrathecal or intravenous software of both autologous or allogenic stem cell transplantation for youngsters with autism spectrum disorder (ASD).

An important element reported whereas interviewing the parents was that youngsters started to respond significantly better and faster to their speech and habits therapy 3-6 months following SCT. Published knowledge counsel that SCT reduces the immunological inflammatory disease of the brain associated with ASD and thus, opens the door for effectiveness of ABA and speech therapy. Indeed, a current proteomic evaluation study found 9 serum proteins to be significantly completely different in ASD in comparison with usually growing boys and a big correlation with ASD severity based on ADOS (24). Possible mechanisms for the best way stem cells improve autism have been discussed more extensively by Liu et al. (25). In summary, two mechanisms appear to prevail: (a) reset of the immunological system and (b) improved vascular perfusion of the mind, two mechanisms which are addressed each by the stem cells but also by the bone marrow plasma, rich in progress hormones.

There may be a big body of knowledge pointing at immune-related genetically coupled risk factors and events related to ASD. A cascade of events, main disruption of neuronal maturation and dysfunctional networking by dysfunctional astrocytic neuronal help. A complete evaluate on this topic was recently published by Liu et al. (25). More curiously, neuropathological investigations have just lately offered proof in support of the inflammatory concept, describing perivascular lymphocytic infiltration within the cerebral white, gray matter, and neuronal leptomeninges, this infiltrates were quantitatively accompanied by a corresponding magnitude of astrocytic activation in the affected areas of the brain. In addition they reported significant loss on neurons and glial cells of the cerebral gray matter immediately adjacent to the leptomeningeal space. Brain micropathology additionally concerned periventricular and other cerebral spinal fluid brain interfaces and vascular ependymal buildings, all contributing to a practical disruption of the blood brain barrier (26, 27).

However, in ASD plainly the overexpression of specific histocompatibility (HLA) genes (chromosome 6) and significantly activating KIR genes (chromosome 19) play an vital position in selling the cellular autoimmune cascade in brain tissue (28). The overexpression of the genes as compared to the general population offers a molecular foundation for understanding occasions triggering a pathological immune response to viral or microbial antigens. BM-derived SCT is capable of targeting these pathological processes within the brain without having rapid and mid-term opposed occasions. The longevity of the impact of BM-derived SCT on suppressing inflammation and derailed autoimmune processes within the central nervous system (29) requires additional investigations in larger cohorts. Furthermore, it is speculated if repeated remedy might have a cumulative impact on ASD. In addition, long-term statement are needed in kids following autologous BM-derived SCT, though low probability, to rule out potential undesirable complications. Addition issues that require further elucidation involve (a) the efficacy and safety of employed cell varieties i.e., allogenic vs. autologous, umbilical cord-derived vs. autologous BM-derived, (b) the route of administration (intravenous vs. intrathecal), and (c) the added worth of injecting BM-derived plasma. Presently, the rather restricted accessible literature signifies more favorable results when employing intrathecal over intravenous route, in all probability as a result of with the later, a lot of the cells might be filtered by the lung parenchyma throughout their first blood passage.

Autologous SCT have a biological benefits over allogenic stem cells and resemble a novel and promising treatment option for autistic kids and adolescent not benefiting from standard symptom-primarily based and behavioral therapy. In ASD affected children offering intrathecal SCT at an earlier age must be related to a better profit, as the mind plasticity and neurogenesis are at their most (30, 31), while perivascular harm to the neuronal circuitry is minimal.

Previous findings indicate that autologous, BM-derived, intrathecally and simultaneously intravenously utilized, level-of-care SCT is a secure therapeutic choice by exhibiting no adversarial events. Furthermore, our findings additionally confirmed enhancements in all 4 ATEC subsets including speech/communication, social habits, sensory/cognitive consciousness and well being/physical conduct. Our and former outcomes by different authors are promising, however mandate additional investigations in a larger managed cohort of patients together with objective methods reminiscent of biomarkers to presumably better perceive the underlying individual dysfunction and potentially permit a stratification of those patients who could benefit most from this treatment technique.

Data Availability Statement

The unique contributions introduced within the study are included in the article/supplementary materials, further inquiries will be directed to the corresponding author/s.

Ethics Statement

Ethical evaluate and approval was not required for the examine on human members in accordance with the native laws and institutional requirements. Written knowledgeable consent to participate in this examine was provided by the individuals' legal guardian/next of kin. Written knowledgeable consent was obtained from the person(s), and minor(s)' legal guardian/subsequent of kin, for the publication of any doubtlessly identifiable pictures or data included in this text.

Author Contributions

GK and BL: wrote the primary draft of the manuscript and coordinated and supervised knowledge collection. GK: an experienced general and cardiac surgeon, carried out all SCTs. GK, JZ, CP, and BL: substantially contributed to interpretation of knowledge for the work and critically reviewed and revised the manuscript for essential mental content. All authors gave their ultimate approval and agreed to be accountable for all aspects of this work guaranteeing its integrity and accuracy.

Conflict of Interest

The authors declare that the research was conducted within the absence of any business or financial relationships that might be construed as a potential battle of interest.

Publisher's Note

All claims expressed in this text are solely those of the authors and do not necessarily symbolize those of their affiliated organizations, or these of the publisher, the editors and the reviewers. Any product which may be evaluated in this article, or declare that could be made by its manufacturer, isn't assured or endorsed by the writer.

Acknowledgments

We gratefully acknowledge the participation of the dad and mom and for allowing us to be taught from their stories. We would like to thank the anesthetist for his excellent efficiency in pediatric anesthesia leading to reduce any postoperative unwanted side effects.

1. Kanner L. Autistic disturbances of affective contact. Nerv Child. (1943) 2:217-50.

2. Robinson EB, Neale BM, Hyman SE. Genetic analysis in autism spectrum disorder. Curr Opin Pediatr. (2015) 27:685-91. doi: 10.1097/MOP.0000000000000278

3. Maenner MJ, Shaw KA, Baio J, Washington A, Patrick M, DiRienzo M, et al. Prevalence of autism spectrum disorder among children aged eight years - autism and developmental disabilities monitoring network, eleven sites, United States. MMWR. (2020) 69:1-12. https://www.cdc.gov/mmwr/volumes/69/ss/ss6904a1.htm?s_cid=ss6904a1_w (accessed September 20, 2021).

4. Lichtenstein P, Carlstrom E, Rastam M, Gillberg C, Anckarster H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry. (2010) 167:1357-63. doi: 10.1176/appi.ajp.2010.10020223

5. Roland A, Happe F, Price TS, Baron-Cohen S, Polmin R. Phenotypic and genetic overlap between autistic traits and their extremes of the general population. J Am Acad Child Aadolesc Psychiatry. (2006) 45:1206-14. doi: 10.1097/01.chi.0000230165.54117.41

6. Constantino JN, Todd RD. Autistic traits in the final population: a twin research. Arch Gen Psychiatry. (2003) 60:524-30. doi: 10.1001/archpsyc.60.5.524

7. Constantino JN, Todorov A, Hilton C, Law P, Zhang Y, Molloy E, et al. Autism recurrence in half siblings: robust assist for genetic mechanisms of transmission in ASD. Mol Psychiatry. (2013) 18:137-8. doi: 10.1038/mp.2012.9

8. Constantino JN, Zhang Y, Frazier T, Abbacchi AM, Law P. Siblings recurrence and the genetic epidemiology of artisan. Am J Psychiatry. (2010) 167:1349-56. doi: 10.1176/appi.ajp.2010.09101470

9. Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Prochazka V, et al. Immunological and autoimmune concerns of autism spectrum disorders. J Autoimmun. (2013) 44:1-7. doi: 10.1016/j.jaut.2013.05.005

10. Gesundheit B, Rosenzweig JP. Editorial: autism spectrum disorders (ASD)-looking for the biological basis for behavioral symptoms and new therapeutic targets. Front Neurosci. (2016) 10:607. doi: 10.3389/fnins.2016.00607

11. Gesundheit B, Ashwood P, Keating A, Naor D, Melamed M, Rosenzweig JP. Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. Med Hypotheses. (2015) 84:169-77. doi: 10.1016/j.mehy.2014.12.016

12. Zhao Y, Huang Z, Qi M, Lazzarini P, Mazzone T. Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunol Lett. (2007) 108:78-87. doi: 10.1016/j.imlet.2006.10.007

13. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. (2008) 8:726-36. doi: 10.1038/nri2395

14. Sharma A, Gokulchandran N, Sane H, Nagrajan A, Paranjape A, Kulkarni P, et al. Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study. Stem Cells Int. (2013) 2013:623-875. doi: 10.1155/2013/623875

15. Thanh LN, Nguyen H-P, Ngo MD, Bui VA, Dam PTM, Bui HTP, et al. Outcome of bone marrow mononuclear cell transplantation mixed with interventional education for autis spectrum disorder. Stem Cells Trans Med. (2021) 10:14-26. doi: 10.1002/sctm.20-0102

16. Whitehouse AJO, Granich J, Alvares G, Busacca M, Cooper MN, Dass A, et al. A randomized controlled trial of an iPad-based mostly application to complement early behavioural intervention in autism spectrum disorder. J Child Psychol Psychiatry. (2017) 58:1042-52. doi: 10.1111/jcpp.12752

17. de Bild A, Oosterling IJ, van Lang NDJ, Systema S, Mideraa RB, van England H, et al. Standardized ADOS scores: measuring severity of autism spectrum disorders in Dutch samples. J Autism Dev Disord. (2011) 41:311-9. doi: 10.1007/s10803-010-1057-zero

18. Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med. (2013) 11:196. doi: 10.1186/1479-5876-11-196

19. Dawson G, Sun JM, Davlantis KS, Murias M, Franz L, Troy J, et al. Autologous cord blood infusions are protected and feasible in young children with autism spectrum disorder: results of a single-center part I open-label trial. Stem Cells Transl Med. (2017) 6:1332-9. doi: 10.1002/sctm.16-0474

20. Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and observations from a placebo-controlled, crossover study to evaluate use of autologous umbilical cord blood stem cells to improve signs in youngsters with autism. Stem Cells Transl Med. (2018) 7:333-41. doi: 10.1002/sctm.17-0042

21. Dawson G, Sun JM, Baker J, Carpenter K, Compton S, Deaver M, et al. A section II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for therapy of children with autism spectrum disorder. J Pediatr. (2020) 222:164-73. doi: 10.1016/j.jpeds.2020.03.011

22. Sharifzadeh N, Ghasemi A, Afshari JT, Moharari F, Soltanifar A, Talaei A, et al. Intrathecal autologous bone marrow stem cell therapy in kids with autism: a randomized managed trial. Asia Pac Psychiatry. (2021) 13:e12445. doi: 10.1111/appy.12445

23. Sharma AK, Gokulchandran N, Kulkarni PP, Sane HM, Sharma R, Jose A, et al. Cell transplantation as a novel therapeutic technique for autism spectrum disorders: a clinical study. Am J Stem Cells. (2020) 9:89-100.

PubMed Abstract | Google Scholar

24. Hewitson L, Mathews JA, Devlin M, Schutte C, Lee J, German DC. Blood biomarker discovery for autism spectrum disorder: a proteomic evaluation. PLoS ONE. (2021) 16:e0246581. doi: 10.1371/journal.pone.0246581

25. Liu Q, Chen MX, Sun L, Wallis CU, Zhou JS, Ao LJ, et al. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders. World J Stem Cells. (2019) 11:55-72. doi: 10.4252/wjsc.v11.i2.55

26. Di Stasio MM, Nagakura I, Nadler MJ, Andreson MP. T-lymphocytes and cytotoxic astrocytic blebs correlate across autism brain. Ann Neuro. (2019) 86:885-98. doi: 10.1002/ana.25610

27. Chaudhuri Ad, Dasgheyb RM, DeVine LR, Bi H, Cole RN, Haughey NJ. Stimulus-dependent modifications in astrocyte-derived extracellular vesicle cargo regulate neuronal excitability. Glia. (2020) 68:128-44. doi: 10.1002/glia.23708

28. Torres AR, Sweeten TL, Cutler A, Bedke BJ, Fillmre M, Stubbs EG, et al. The association and linkage of the HLA-A2 class I allele with autism. Hum Immunol. (2006) 67:346-51. doi: 10.1016/j.humimm.2006.01.001

29. Pardo CA, Farmer CA, Thurm A, Shebl FM, Ilieva J, Kalra S, et al. Serum and cerebrospinal fluid immune mediators in youngsters with autistic disorder: a longitudinal examine. Mol Autism. (2017) 8:1. doi: 10.1186/s13229-016-0115-7

30. Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in adult human hippocampus. Nat Med. (1998) 4:1313-7. doi: 10.1038/3305

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Knoth R, Singec I, Ditter M, Pantazis G, Capetian P, Meyer RP, et al. Murine options of neurogenesis in the human hippocampus across the lifespan from 0 to a hundred years. PLoS ONE.

If you have any sort of concerns pertaining to where and how you can make use of https://autismtreatmentcare.com/, you could contact us at our web site.